Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FOLH1 | Q04609 | 9/20 | 1.00 |
| ▸ | NAALAD2 | Q9Y3Q0 | 5/20 | 0.68 |
| ▸ | ALB | P02768 | 7/20 | 0.53 |
| ▸ | IL2 | P60568 | 7/20 | 0.53 |
| ▸ | RIMKLA | Q8IXN7 | 1/20 | 0.53 |
| ▸ | TNF | P01375 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4139164 | 1.00 | FOLH1 (1.00) | FOLH1NAALAD2ALBIL2RIMKLA | |
| SCHEMBL11941065 | 0.90 | FOLH1 (0.81) | FOLH1NAALAD2ALBIL2TNF | |
| SCHEMBL11930754 | 0.85 | FOLH1 (0.74) | FOLH1NAALAD2RIMKLA | |
| SCHEMBL13559316 | 0.84 | FOLH1 (0.73) | FOLH1NAALAD2 | |
| SCHEMBL4317843 | 0.83 | NAALAD2 (0.77) | FOLH1NAALAD2RIMKLA | |
| SCHEMBL11936648 | 0.83 | NAALAD2 (0.77) | FOLH1NAALAD2RIMKLA | |
| SCHEMBL4317844 | 0.83 | NAALAD2 (0.77) | FOLH1NAALAD2RIMKLA | |
| SCHEMBL4132676 | 0.83 | NAALAD2 (0.77) | FOLH1NAALAD2RIMKLA | |
| SCHEMBL13515316 | 0.81 | NAALAD2 (1.00) | FOLH1NAALAD2RIMKLA | |
| SCHEMBL9965331 | 0.81 | NAALAD2 (1.00) | FOLH1NAALAD2RIMKLA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 45 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230095637-A1 | Heterodimers of Glutamic Acid | CITIZENS BANK, N.A. | 2023-03-30 | — | — | US | disclosed |
| EP-4023624-A1 | HETERODIMERS OF GLUTAMIC ACID | Molecular Insight Pharmaceuticals, Inc. (US) | 2022-07-06 | — | — | EP | disclosed |
| EP-3699162-B1 | HETERODIMERS OF GLUTAMIC ACID | MOLECULAR INSIGHT PHARM INC (US) | 2022-06-29 | — | — | EP | disclosed |
| US-20210246103-A1 | HETERODIMERS OF GLUTAMIC ACID | CITIZENS BANK, N.A. | 2021-08-12 | — | — | US | disclosed |
| US-20210070695-A1 | HETERODIMERS OF GLUTAMIC ACID | MOLECULAR INSIGHT PHARMACEUTICALS, INC. | 2021-03-11 | — | — | US | disclosed |
| US-20210070696-A1 | HETERODIMERS OF GLUTAMIC ACID | MOLECULAR INSIGHT PHARMACEUTICALS, INC. | 2021-03-11 | — | — | US | disclosed |
| EP-3335736-B1 | HETERODIMERS OF GLUTAMIC ACID | MOLECULAR INSIGHT PHARM INC (US) | 2020-12-30 | — | — | EP | disclosed |
| EP-3699162-A1 | HETERODIMERS OF GLUTAMIC ACID | Molecular Insight Pharmaceuticals, Inc. (US) | 2020-08-26 | — | — | EP | disclosed |
| US-10647666-B2 | Heterodimers of glutamic acid | MOLECULAR INSIGHT PHARMACEUTICALS, INC. (US) | 2020-05-12 | — | — | US | disclosed |
| US-10640461-B2 | Heterodimers of glutamic acid | MOLECULAR INSIGHT PHARMACEUTICALS, INC. (US) | 2020-05-05 | — | — | US | disclosed |
| US-8227634-B2 | Imaging agents and methods of imaging NAALADase or PSMA | POMPER MARTIN GILBERT (US) | 2012-07-24 | — | — | US | disclosed |
| US-8211401-B2 | Technetium- and rhenium-bis(heteroaryl) complexes and methods of use thereof for inhibiting PSMA | MOLECULAR INSIGHT PHARMACEUTICALS, INC. (US) | 2012-07-03 | — | — | US | disclosed |
| EP-2389361-A2 | TECHNETIUM- AND RHENIUM-BIS(HETEROARYL) COMPLEXES AND METHODS OF USE THEREOF FOR INHIBITING PSMA | Molecular Insight Pharmaceuticals, Inc. (US) | 2011-11-30 | — | — | EP | disclosed |
| US-20100178246-A1 | TECHNETIUM- AND RHENIUM-BIS(HETEROARYL) COMPLEXES AND METHODS OF USE THEREOF FOR INHIBITING PSMA | MOLECULAR INSIGHT PHARMACEUTICALS, INC. | 2010-07-15 | — | — | US | disclosed |
| WO-2010065902-A2 | TECHNETIUM- AND RHENIUM-BIS(HETEROARYL) COMPLEXES AND METHODS OF USE THEREOF FOR INHIBITING PSMA | MOLECULAR INSIGHT PHARMACEUTICALS, INC. (US) | 2010-06-10 | — | — | WO | disclosed |
| EP-2097111-A2 | HETERODIMERS OF GLUTAMIC ACID | Molecular Insight Pharmaceuticals, Inc. (US) | 2009-09-09 | — | — | EP | disclosed |
| US-20090117042-A1 | Imaging agents and methods of imaging NAALADase or PSMA | THE JOHNS HOPKINS UNIVERSITY (US) | 2009-05-07 | — | — | US | disclosed |
| US-20080193381-A1 | HETERODIMERS OF GLUTAMIC ACID | MOLECULAR INSIGHT PHARMACEUTICALS, INC. | 2008-08-14 | — | — | US | disclosed |
| US-7408079-B2 | Imaging prostate cancer | THE JOHNS HOPKINS UNIVERSITY (US) | 2008-08-05 | — | — | US | disclosed |
| WO-2008058192-A2 | HETERODIMERS OF GLUTAMIC ACID | MOLECULAR INSIGHT PHARMACEUTICALS, INC. (US) | 2008-05-15 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100178246-A1 | TECHNETIUM- AND RHENIUM-BIS(HETEROARYL) COMPLEXES AND METHODS OF USE THEREOF FOR INHIBITING PSMA | PSMA1, PSMA5, PSMA3 | FOLH1 4/4885NAALAD2 339/4885ALB 825/4885 |
| US-20210070695-A1 | HETERODIMERS OF GLUTAMIC ACID | DDO, GLUL, ASNS | FOLH1 5/4885NAALAD2 7/4885ALB 2572/4885 |
| US-20090117042-A1 | Imaging agents and methods of imaging NAALADase or PSMA | FOLH1, DNPEP, NAALAD2 | FOLH1 1/4885NAALAD2 3/4885ALB 1718/4885 |
| US-10647666-B2 | Heterodimers of glutamic acid | DDO, GLUL, ASNS | FOLH1 5/4885NAALAD2 7/4885ALB 2572/4885 |
| US-20080193381-A1 | HETERODIMERS OF GLUTAMIC ACID | DDO, GLUL, ASNS | FOLH1 5/4885NAALAD2 7/4885ALB 2572/4885 |
| US-20210070696-A1 | HETERODIMERS OF GLUTAMIC ACID | DDO, GLUL, ASNS | FOLH1 5/4885NAALAD2 7/4885ALB 2620/4885 |
| US-20230095637-A1 | Heterodimers of Glutamic Acid | DDO, GLUL, ASNS | FOLH1 5/4885NAALAD2 9/4885ALB 2882/4885 |
| US-10640461-B2 | Heterodimers of glutamic acid | DDO, GLUL, ASNS | FOLH1 5/4885NAALAD2 7/4885ALB 2572/4885 |
| US-20210246103-A1 | HETERODIMERS OF GLUTAMIC ACID | DDO, GLUL, ASNS | FOLH1 5/4885NAALAD2 7/4885ALB 2572/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.